Chronic Liver Diseases Therapeutics Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the chronic liver diseases therapeutics market grown in recent years?
The market size for therapeutics pertaining to chronic liver disease has experienced significant expansion in the recent past. The market, which was valued at $14.38 billion in 2024, is expected to elevate to $15.92 billion in 2025, showing a compound annual growth rate (CAGR) of 10.7%. The historical growth in this market can be attributed to factors such as the escalations in cases of viral hepatitis, elevated rates of obesity, demographics shifting towards an aging population, increased cognizance surrounding liver health, and enhanced accessibility to treatment for patients.
How is the chronic liver diseases therapeutics market size expected to evolve during the forecast period?
The market for therapeutics for chronic liver disease is projected to experience swift expansion in the coming years, expected to reach a valuation of $23.83 billion in 2029, growing at a compound annual growth rate of 10.6%. This growth can be attributed to an increased emphasis on personalised medicine, a growing range of innovative therapies in the pipeline, and an expansion of telemedicine and digital health solutions. Other factors include a heightened demand for liver disease prevention initiatives and growing incidence of viral hepatitis. Notable trends include the incorporation of artificial intelligence in diagnostics, the advancements in gene and biologic therapies, the development of non-invasive treatment methods, the application of combination therapies, and the broadening of patient-centric care models.
Get your chronic liver diseases therapeutics market report here!
Which key drivers are propelling the chronic liver diseases therapeutics market’s growth?
The rise in alcohol consumption is anticipated to boost the advancement of the market for therapeutic treatment of chronic liver disease. Drinking alcoholic beverages, which contain ethanol, can vary from moderate to excessive use and may affect health. The growth in alcohol use is attributed to its increased social acceptability, higher income levels, and improved accessibility worldwide. Therapies for chronic liver disease aim to manage liver damage triggered by excessive alcohol consumption, decelerating disease advancement and enhancing liver function. It is worth mentioning, for example, that as per the First Citizens Bank, a financial institution based in the US, there was a 1.2% rise in direct-to-consumer (DTC) wine case sales in 2023 compared to 2022, in June 2024. Also, in December 2023, a report from Kirin Holdings Company Limited, a Japanese beverage company, disclosed that approximately 192.1 million kiloliters of beer were consumed in 2022, showing a 2.9% increase from the previous year. Consequently, the growing consumption of alcohol is fueling the expansion of the market for chronic liver disease therapeutics.
What are the market segments in the chronic liver diseases therapeutics industry?
The chronic liver diseases therapeutics market covered in this report is segmented –
1) By Treatment Type: Antiviral Drugs, Immunosuppressants Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy
2) By Disease Type: Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Cancer, Genetic Disorders
3) By Application: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Antiviral Drugs: Nucleoside Or Nucleotide Analogues, Interferons, Direct-Acting Antivirals
2) By Immunosuppressants: Calcineurin Inhibitors, mTOR Inhibitors, Purine Synthesis Inhibitors
3) By Vaccines: Hepatitis A Vaccine, Hepatitis B Vaccine, Combination Hepatitis Vaccines
4) By Immunoglobulins: Hepatitis B Immune Globulin, Intravenous Immunoglobulin
5) By Corticosteroids: Prednisolone, Methylprednisolone, Dexamethasone
6) By Targeted Therapy: Tyrosine Kinase Inhibitors, Monoclonal Antibodies
7) By Chemotherapy: Systemic Chemotherapy, Transarterial Chemoembolization Agents
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21145&type=smp
Which leading companies are shaping the growth of the chronic liver diseases therapeutics market?
Major companies operating in the chronic liver diseases therapeutics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Dr. Reddy’s Laboratories Ltd., Vir Biotechnology Inc., Alnylam Pharmaceuticals Inc., Indian Immunologicals Limited, Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Ascletis Pharma Inc., Ochre Bio Limited, Tiziana Life Sciences Ltd., Antios Therapeutics Inc.
What are the key trends shaping the future of the chronic liver diseases therapeutics market?
Key players in the therapeutics market for chronic liver diseases are concentrating on creating advancements like RNA therapies that aim at genetic and molecular mechanisms, providing more efficient and customized treatment choices. RNA therapies, modern medical treatments that use RNA molecules to control gene expression or protein creation, work towards treating or preventing diseases by focusing on particular genetic mechanisms. For example, Ochre Bio, a biotech firm based in the UK, initiated their groundbreaking ‘Liver ICU’ research facility at BioLabs@NYULangone, a biopharmaceutical incubator located in New York City, in May 2022. This cutting-edge site evaluates the potency of next-gen RNA therapeutics by utilizing whole human livers maintained on perfusion devices. The facility’s goal is to expedite the drug development process and enhance the accuracy of liver treatment studies by imitating human physiological states, using rejected donor livers for research purposes.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21145
Which geographic areas are influencing the growth of the chronic liver diseases therapeutics market?
North America was the largest region in the chronic liver diseases therapeutics market in 2024. The regions covered in the chronic liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Urothelial Carcinoma Treatment Global Market Report 2025
Mineral And Bone Disorder Treatment Global Market Report 2025
Pancreatic Cancer Drugs Global Market Report 2025
https://thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
